{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T14:24:54Z","timestamp":1783347894410,"version":"3.54.6"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Inflammatory bowel diseases (IBD), including Crohn\u2019s disease (CD), and ulcerative colitis (UC), are chronic autoimmune disorders with increasing prevalence in Saudi Arabia (KSA). Understanding patient treatment preferences is important for improving adherence and quality of life. This study evaluated treatment preferences in KSA within the context of the overall five-country cohort (Argentina, Australia, Brazil, Taiwan, and KSA), without conducting formal cross-country comparisons.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A cross-sectional survey (October 2022\u2013May 2023) used discrete choice experiments (DCE) to assess preferences for treatment attributes, including safety, efficacy, and route of administration (RoA). Adults (\u226518 years) with self-reported CD or UC receiving treatment for \u22656 months were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Data from 353 patients with CD and 353 with UC were analyzed, including 102 from KSA (51 CD, 51 UC). Preferences in KSA were largely consistent with the overall cohort. CD patients prioritized long-term remission, while UC patients valued corticosteroid-free remission at 1 year. Descriptively, KSA patients appeared to place relatively greater emphasis on safety attributes compared with the overall cohort\u2014particularly serious adverse events (AEs) in both CD and UC, and mild AEs in UC\u2014and less emphasis on mucosal healing and RoA. Abdominal pain (CD) and rectal bleeding (UC) most affected quality of life and daily activities. KSA patients also reported lower exposure to advanced therapies (0% in CD and 11.8% in UC). However, given the limited sample size and absence of formal statistical testing, these observations between countries should be interpreted as exploratory.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Personalized IBD management in KSA is needed. Incorporating patient preferences into clinical decision-making may improve adherence and outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/sjg.sjg_89_26","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T13:50:00Z","timestamp":1783345800000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Patient preferences toward the attributes of treatment used for inflammatory bowel disease in Saudi Arabia: Subgroup analysis from an international multicenter discrete choice experiment"],"prefix":"10.4103","author":[{"given":"Nahla","family":"Azzam","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Mourad","sequence":"additional","affiliation":[{"name":"Medical Affairs and Patient Services (PSP), EAMEA (Eurasia, Middle East and Africa), Takeda Pharmaceuticals FZE (Lebanon Rep Office), Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Mosli","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia"},{"name":"Inflammatory Bowel Disease Unit, King Abdulaziz University Hospital, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman","family":"Al Sulais","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, King Fahad Specialist Hospital, Dammam, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansour","family":"Altuwaijri","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaser","family":"Meeralam","sequence":"additional","affiliation":[{"name":"Digestive and Liver Health and Advanced Endoscopy Center, King Abdullah Medical City, Makkah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Fadeeva","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Takeda Pharmaceuticals International AG, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Elgharbawy","sequence":"additional","affiliation":[{"name":"Medical Affairs \u2013 West Gulf Countries, Takeda Regional Headquarters Company, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"R1-20260706","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2147\/JIR.S65979","article-title":"Inflammatory bowel disease: Clinical aspects and treatments","volume":"7","author":"Fakhoury","year":"2014","journal-title":"J Inflamm Res"},{"key":"R2-20260706","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.dld.2023.04.003","article-title":"The global, regional, and national burden of inflammatory bowel diseases, 1990-2019: A systematic analysis for the global burden of disease study 2019","volume":"55","author":"Park","year":"2023","journal-title":"Dig Liver Dis"},{"key":"R3-20260706","first-page":"1627","article-title":"Inflammatory bowel disease: Cause and immunobiology","volume":"369","author":"Baumgart","year":"2007","journal-title":"Lancet Glob Health"},{"key":"R4-20260706","first-page":"527","article-title":"Inflammatory bowel disease burden in the Middle East and North Africa Region: A comprehensive analysis of incidence, prevalence, and mortality from 1990-2019","volume":"37","author":"Alsakarneh","year":"2024","journal-title":"Ann Gastroenterol"},{"key":"R5-20260706","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(19)30333-4","article-title":"The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017","volume":"5","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R6-20260706","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.4103\/sjg.sjg_277_22","article-title":"Saudi Arabia consensus guidance for the diagnosis and management of adults with inflammatory bowel disease","volume":"29","author":"Mosli","year":"2023","journal-title":"Saudi J Gastroenterol"},{"key":"R7-20260706","first-page":"2779","article-title":"Effect of tight control management on Crohn's disease (CALM): A multicentre, randomised, controlled phase 3 trial","volume":"390","author":"Colombel","year":"2017","journal-title":"Lancet Glob Health"},{"key":"R8-20260706","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40271-019-00407-5","article-title":"A qualitative research for defining meaningful attributes for the treatment of inflammatory bowel disease from the patient perspective","volume":"13","author":"Louis","year":"2020","journal-title":"Patient"},{"key":"R9-20260706","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1093\/ibd\/izae015","article-title":"Patient preferences for treatment attributes in inflammatory bowel disease: Results from a large survey across seven European countries using a discrete choice experiment","volume":"30","author":"Fiorino","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"R10-20260706","doi-asserted-by":"crossref","first-page":"3922","DOI":"10.1007\/s12325-025-03249-w","article-title":"Patient preferences for treatment attributes in inflammatory bowel disease: A discrete choice experiment among patients in five non-western countries","volume":"42","author":"Argollo","year":"2025","journal-title":"Adv Ther"},{"key":"R11-20260706","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.drudis.2019.05.001","article-title":"Methods for exploring and eliciting patient preferences in the medical product lifecycle: A literature review","volume":"24","author":"Soekhai","year":"2019","journal-title":"Drug Discov Today"},{"key":"R12-20260706","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.jval.2019.04.1924","article-title":"Are healthcare choices predictable? The impact of discrete choice experiment designs and models","volume":"22","author":"de Bekker-Grob","year":"2019","journal-title":"Value Health"},{"key":"R13-20260706","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","article-title":"Conjoint analysis applications in health \u2013 A checklist: A report of the ISPOR good research practices for conjoint analysis task force","volume":"14","author":"Bridges","year":"2011","journal-title":"Value Health"},{"key":"R14-20260706","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1007\/s12325-022-02143-z","article-title":"Inflammatory bowel disease patients'treatment preferences using a discrete choice experiment technique: The InPuT study","volume":"39","author":"Schubert","year":"2022","journal-title":"Adv Ther"},{"key":"R16-20260706","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s40271-015-0118-z","article-title":"Sample size requirements for discrete-choice experiments in healthcare: A practical guide","volume":"8","author":"de Bekker-Grob","year":"2015","journal-title":"Patient"},{"key":"R17-20260706","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12664-022-01303-x","article-title":"Diagnostic delay in adult inflammatory bowel disease: A systematic review","volume":"42","author":"Cross","year":"2023","journal-title":"Indian J Gastroenterol"},{"key":"R18-20260706","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000529318","article-title":"A Regional survey of awareness of inflammatory bowel disease among the Saudi population","volume":"7","author":"Meeralam","year":"2022","journal-title":"Inflamm Intest Dis"},{"key":"R19-20260706","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12962-019-0194-3","article-title":"Drug utilization and cost associated with inflammatory bowel disease management in Saudi Arabia","volume":"17","author":"AlRuthia","year":"2019","journal-title":"Cost Eff Resour Alloc"},{"key":"R20-20260706","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/MOG.0b013e32832b764b","article-title":"Making therapeutic decisions in inflammatory bowel disease: The role of patients","volume":"25","author":"Siegel","year":"2009","journal-title":"Curr Opin Gastroenterol"},{"key":"R21-20260706","doi-asserted-by":"crossref","first-page":"157","DOI":"10.5009\/gnl210118","article-title":"Long-term disease course of Crohn's disease: Changes in disease location, phenotype, activities, and predictive factors","volume":"16","author":"Cho","year":"2022","journal-title":"Gut Liver"},{"key":"R22-20260706","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/BF02253508","article-title":"Steroid complications in patients with ulcerative colitis","volume":"35","author":"Kusunoki","year":"1992","journal-title":"Dis Colon Rectum"},{"key":"R23-20260706","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.3390\/jcm13061630","article-title":"Coping strategies and inflammatory bowel disease: A narrative review","volume":"13","author":"Popa","year":"2024","journal-title":"J Clin Med"},{"key":"R24-20260706","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s11136-013-0508-4","article-title":"Fatigue interference with daily living among patients with inflammatory bowel disease","volume":"23","author":"Opheim","year":"2014","journal-title":"Qual Life Res"}],"container-title":["Saudi Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.4103\/sjg.sjg_89_26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T13:50:04Z","timestamp":1783345804000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.4103\/sjg.sjg_89_26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":23,"URL":"https:\/\/doi.org\/10.4103\/sjg.sjg_89_26","relation":{},"ISSN":["1319-3767","1998-4049"],"issn-type":[{"value":"1319-3767","type":"print"},{"value":"1998-4049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"2026-02-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}